IKT - Inhibikase Therapeutics Inc
IEX Last Trade
1.39
0.003 0.252%
Share volume: 3,098
Last Updated: Fri 30 Aug 2024 08:39:54 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$1.39
0.00
0.25%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-12 | 2022-11-14 | 2023-03-31 | 2023-05-15 | 2023-08-14 | 2023-11-14 | 2024-03-27 | 2024-05-15 | |
| Assets | |||||||||
| Total Assets | 33.992 M | 28.581 M | 24.936 M | 28.163 M | 22.347 M | 17.881 M | 14.507 M | 11.068 M | |
| Current Assets | 33.949 M | 27.986 M | 24.371 M | 27.629 M | 21.984 M | 17.551 M | 14.211 M | 10.808 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 1.731 M | 1.438 M | 1.281 M | 1.846 M | 969.152 K | 719.103 K | 958.996 K | 1.058 M | |
| Short Term Investments | 1.731 M | 1.438 M | 1.281 M | 1.846 M | 969.152 K | 719.103 K | 958.996 K | 1.058 M | |
| Total Receivables | 6.552 K | 13.842 K | 39.881 K | 64.521 K | 79.604 K | 0.000 | 0.000 | 0.000 | |
| Current Cash | 32.212 M | 26.534 M | 23.050 M | 25.718 M | 20.935 M | 16.832 M | 13.252 M | 9.749 M | |
| Total Non-current Assets | 43.089 K | 594.824 K | 565.175 K | 534.752 K | 363.615 K | 330.030 K | 295.599 K | 260.264 K | |
| Property Plant Equipment | 43.089 K | 241.574 K | 236.532 K | 231.489 K | 86.523 K | 79.940 K | 73.372 K | 66.804 K | |
| Other Assets | 0.000 | 353.250 K | 328.643 K | 303.263 K | 277.092 K | 250.090 K | 222.227 K | 193.460 K | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 33.992 M | 28.581 M | 24.936 M | 28.163 M | 22.347 M | 17.881 M | 14.507 M | 11.068 M | |
| Total liabilities | 4.490 M | 3.445 M | 3.901 M | 2.842 M | 2.883 M | 2.863 M | 3.529 M | 4.291 M | |
| Total current liabilities | 4.490 M | 3.213 M | 3.695 M | 2.664 M | 2.733 M | 2.742 M | 3.439 M | 4.233 M | |
| Accounts Payable | 860.444 K | 781.223 K | 1.151 M | 959.078 K | 754.146 K | 734.561 K | 646.767 K | 1.294 M | |
| Other liabilities | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current long term debt | 0.000 | 142.048 K | 145.836 K | 146.901 K | 147.966 K | 149.030 K | 531.879 K | 431.773 K | |
| Long term debt | 0.000 | 232.020 K | 205.451 K | 178.110 K | 149.971 K | 121.013 K | 90.124 K | 58.330 K | |
| Other liabilities | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 29.502 M | 25.136 M | 21.035 M | 25.321 M | 19.464 M | 15.018 M | 10.978 M | 6.777 M | |
| Common stock | 4.205 M | 4.205 M | 4.198 M | 4.585 M | 5.226 M | 5.342 M | 6.179 M | 6.341 M | |
| Retained earnings | -39.098 M | -43.593 M | -47.872 M | -52.350 M | -58.128 M | -62.723 M | -66.901 M | -71.550 M |